Full-Time

Manager – Clinical Supply Chain

Logistics

Posted on 2/10/2026

BeOne

BeOne

1,001-5,000 employees

Global oncology therapeutics discovery, development, manufacturing

Compensation Overview

$114.6k - $154.6k/yr

+ Bonus + Equity Awards

Remote in USA + 1 more

More locations: San Carlos, CA, USA

Hybrid

null

Category
Operations & Logistics (1)
Requirements
  • Bachelor’s degree or above and 7+ years of related experience is required.
  • Travel as needed.
  • Computer Skills: Microsoft Office.
Responsibilities
  • Focusing mainly on the Depot storage, site distribution, drug return & destruction and logistics related Depot performance management in AMER regions.
  • Work with Supply Chain Lead and depot PM setting up distribution and return/destruction procedures for studies following the logistics related procedures.
  • Coordinate drug destruction at depot level regularly following BeOne internal procedure, ensure all certificate of destructions and executed disposition reports are archived and uploaded onto e-TMF accurately and timely.
  • Well manage the depot monthly reports and implement regular stock-taking and reconciliation for depot storage as needed.
  • Supports on Storage Insurance data calculation and reporting.
  • Coordinate or directly organize site to site transfer shipments as needed.
  • Arrange new depot vendor onboarding trainings per business requirement.
  • Support on new system development and well maintain the logistics data and functions in existing system.
  • Work with internal departments to deal with Logistics related issues as needed, for example, QA, Finance, Tax, Procurement, Legal and RA.
  • Coordinate with external authorities to deal with Logistics issues as needed, for example, Customs and FDA.
  • Coordinate internal or external functions for the Import and export permit application as needed.
  • Understand how to use IRT to check shipment status as needed.
  • Ensure the logistics data entry and documents uploading in BeOne systems could be performed accurately and timely as per BeOne related procedures.
  • Support on BeOne IOR and import tax deferral setup, managing BeOne IOR in different countries, giving greenlight approval and supporting the corresponding import VAT refund as needed.
  • Perform all responsibilities in compliance with internal procedures and external regulations related to import and export activities, brings compliance issues to the attention of management.
  • Lead and measure processes to ensure logistics operations are completed with excellence on regular basis.
  • Collaborate with QA counterparts to ensure audit readiness and process control for all import and export activities, participate in logistics audits as needed.
  • Support SCL on FDA inspection, internal audit and external audit as needed on logistics data preparation per study or compound level.
  • Facilitate and coordinate with courier and depot vendors on all aspects of service, including pre-conditioned shipping containers/materials, temperature data loggers, pick up appointments, expedited orders and emergency delivery situations.
  • Manage and assess Depot vendor’s performance and report Depot metrics (KPIs) to senior management.
  • Ensure the requirements and business process associated with cross-border movements function smoothly, and issues and risks are identified and managed efficiently.
  • Set up deviations, corrective action, and preventive action as necessary in BeOne quality system for logistics incidents, collaborate with internal and external parties to investigate the incident appropriately.
  • Support and oversee daily and ongoing expenses to ensure that financial capital is used as efficiently as possible.
  • Thoroughly review all training materials, Work Instructions (WI), Standard Operating Procedures (SOP), and Global Standard (GS) to ensure complete understanding and alignment with job requirements.
  • Promptly review and respond in writing to all managerial directions. Consult with line manager in a timely manner if there are any questions or uncertainties.
  • Remain vigilant and proactive in keeping up to date with the latest requirements and updates related to the role.
  • Schedule regular meetings with line manager or function owners to ensure ongoing alignment and address any discrepancies or concerns.
  • Evaluate the accuracy, thoroughness, and timely completion of assigned tasks, ensuring to meet the standards of job requirements and expectations.
  • Follow the Logistics team requirement, respond to urgent request/GL approval within 24 hours, reply to all emails within 2 working days.
  • Record and actively monitor the tasks/routine jobs with the target to meet all deadlines constantly.
  • Maximize working productivity by leveraging company-provided tools and platforms, such as Outlook, OneNote, Excel, Smartsheet, and eLogistics.
  • Consult with managers or process owners for clarification on any uncertainties or for additional guidance, ensuring direct support and expertise is readily available.
  • Proactively participate in training sessions provided by various functional teams to broaden knowledge and enhance skill sets across different areas of the organization.
  • Timely finish the assigned trainings associated with Work Instructions (WI), Standard Operating Procedures (SOP), and Global Standards (GS) through the electronic Learning Management System as well as the assigned courses in BeOne University
  • Perform other duties as assigned in a dynamic "start-up" environment.
  • Proficiency with Mandarin is highly preferred.
Desired Qualifications
  • Proficiency with Mandarin is highly preferred.

BeOne Medicines develops and commercializes cancer therapies for patients worldwide, focusing on hematologic cancers and solid tumors. Its products, including Brukinsa, are sold globally and supported by licensing partnerships, with internal R&D and clinical development driving a broad late-stage pipeline. BeOne differentiates itself by leveraging a large-scale clinical trial network and cost-efficient global drug development to achieve high margins while pursuing large-market indications. The company aims to expand into immunology and solid tumors while maintaining strong investment in R&D to make high-impact, accessible oncology treatments available in more than 45 countries.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dongcheng District, China

Founded

2010

Simplify Jobs

Simplify's Take

What believers are saying

  • Brukinsa generated $1.1 billion in first-quarter 2026 sales, up 38%.
  • Sonrotoclax won FDA accelerated approval for relapsed or refractory mantle cell lymphoma.
  • TEVIMBRA plus ZIIHERA holds FDA Priority Review for HER2-positive gastric cancer.

What critics are saying

  • Revenue remains heavily dependent on Brukinsa, exposing BeOne to competitive erosion.
  • Sonrotoclax's approval depends on CELESTIAL-RRMCL confirmatory results.
  • TEVIMBRA diversification is unproven, with revenue still trailing Brukinsa materially.

What makes BeOne unique

  • BeOne combines Brukinsa, Tevimbra, and sonrotoclax across blood and solid tumors.
  • Its global trial network spans 30,000 patients and 75 approval markets.
  • Brukinsa remains the only BTK inhibitor with head-to-head PFS superiority.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at BeOne who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

Wellness Program

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

-16%

1 year growth

-19%

2 year growth

-13%
Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Feb 26th, 2026
BeOne Medicines reports $1.5B revenue, up 33% despite EPS miss in Q4

BeOne Medicines reported $1.5 billion in revenue for the quarter ended December 2025, a 32.8% year-over-year increase, beating the Zacks Consensus Estimate by 3.19%. The company posted earnings per share of $0.58, compared to a loss of $1.43 in the prior year, though this fell short of the $1.60 consensus estimate. Net product revenues reached $1.48 billion, exceeding the $1.45 billion analyst estimate. BRUKINSA generated $1.15 billion, surpassing the $1.09 billion estimate, whilst TEVIMBRA contributed $182 million, slightly below the $191.33 million forecast. The stock has returned 0.6% over the past month, matching the S&P 500's performance. BeOne currently holds a Zacks Rank of 2, indicating potential outperformance.

Business Wire
Feb 26th, 2026
BeOne Medicines reports $5.3B full-year revenue as BRUKINSA sales surge 49%

BeOne Medicines reported fourth quarter 2025 product revenues of $1.5 billion and full-year revenues of $5.3 billion, representing growth of 32% and 40% year-over-year respectively. Product revenue accounted for 99% of total revenue. BRUKINSA, the company's BTK inhibitor, achieved global sales of $1.1 billion in Q4 and $3.9 billion for the full year, up 38% and 49% respectively. US sales reached $845 million in Q4 and $2.8 billion annually. TEVIMBRA generated $182 million in Q4 and $737 million for the year. The company reported GAAP net income of $67 million in Q4 and $287 million for the full year, compared to losses in prior-year periods. Free cash flow reached $942 million for 2025, up $1.6 billion year-over-year. BeOne provided 2026 guidance of $6.2–6.4 billion in total revenue and $1.4–1.5 billion in non-GAAP operating income.

Yahoo Finance
Feb 2nd, 2026
BeOne Medicines trades at $340 with 51% annual return amid undervaluation signals

BeOne Medicines is trading at $340.38, representing a 9.44% year-to-date gain and 51.29% total shareholder return over the past year, though recent performance has been mixed with a one-day decline and flat weekly performance. The company appears undervalued against an estimated fair value of $401.52, based on strong revenue growth fundamentals. BeOne reported 41% year-over-year revenue growth in Q2 and raised full-year guidance to $5–5.3 billion, driven by demand for its oncology therapy BRUKINSA. The valuation narrative assumes continued aggressive expansion and rising profitability, supported by an ageing population and increased global healthcare spending. However, risks include potential competition affecting BRUKINSA revenues and possible delays in late-stage trials or regulatory approvals.

TipRanks
Nov 20th, 2025
BeOne Medicines Secures $1 Billion Financing Agreement - TipRanks.com

BeOne Medicines ( ($ONC) ) has shared an announcement. On November 13, 2025, BeOne Medicines Ltd. entered into a Facilities Agreement with HSBC and other financial ...

INACTIVE